Characteristics of the 55 Allogeneic Stem Cell Transplantation Procedures
| . | Marrow Fibrosis . | Overall Group n = 55 . | |
|---|---|---|---|
| Grade I-II n = 28 . | Grade III n = 27 . | ||
| Origin of the graft | |||
| Bone marrow | 24 | 25 | 49 |
| Peripheral blood | 4 | 2 | 6 |
| Nucleated cell dose infused (×10E8/kg) − median (range) | 2.5 | 2.7 | 2.7 |
| (0.2-21.8) | |||
| Donor/recipient HLA matching | |||
| HLA matched related | 23 | 26 | 49 |
| HLA class-I mismatched related | 1 | 0 | 1 |
| HLA class-DR mismatched related | 2 | 0 | 2 |
| HLA matched unrelated | 2 | 1 | 3 |
| Conditioning regimen | |||
| Cyclophosphamide + TBI | 9 | 10 | 19 |
| Cyclophosphamide + TBI + etoposide or thiotepa | 4 | 3 | 7 |
| Busulfan + cyclophosphamide | 7 | 10 | 17 |
| Conditioning regimens with TBI | 19 | 16 | 35 |
| GVHD prophylaxis | |||
| Cyclosporine A + methotrexate | 21 | 22 | 43 |
| Cyclosporine A + methotrexate + corticosteroids | 2 | 2 | 4 |
| Other prophylaxis | 5 | 3 | 8 |
| T-cell depletion | 3 | 2 | 5 |
| . | Marrow Fibrosis . | Overall Group n = 55 . | |
|---|---|---|---|
| Grade I-II n = 28 . | Grade III n = 27 . | ||
| Origin of the graft | |||
| Bone marrow | 24 | 25 | 49 |
| Peripheral blood | 4 | 2 | 6 |
| Nucleated cell dose infused (×10E8/kg) − median (range) | 2.5 | 2.7 | 2.7 |
| (0.2-21.8) | |||
| Donor/recipient HLA matching | |||
| HLA matched related | 23 | 26 | 49 |
| HLA class-I mismatched related | 1 | 0 | 1 |
| HLA class-DR mismatched related | 2 | 0 | 2 |
| HLA matched unrelated | 2 | 1 | 3 |
| Conditioning regimen | |||
| Cyclophosphamide + TBI | 9 | 10 | 19 |
| Cyclophosphamide + TBI + etoposide or thiotepa | 4 | 3 | 7 |
| Busulfan + cyclophosphamide | 7 | 10 | 17 |
| Conditioning regimens with TBI | 19 | 16 | 35 |
| GVHD prophylaxis | |||
| Cyclosporine A + methotrexate | 21 | 22 | 43 |
| Cyclosporine A + methotrexate + corticosteroids | 2 | 2 | 4 |
| Other prophylaxis | 5 | 3 | 8 |
| T-cell depletion | 3 | 2 | 5 |
Abbreviation: TBI, total body irradiation.